HITE Hedge Asset Management LLC Reduces Stock Holdings in Ralliant Corporation $RAL

HITE Hedge Asset Management LLC decreased its holdings in Ralliant Corporation (NYSE:RAL) by 40.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 141,390 shares of the company’s stock after selling 95,957 shares during the quarter. HITE Hedge Asset Management LLC owned about 0.13% of Ralliant worth $7,198,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Danske Bank A S purchased a new position in Ralliant during the fourth quarter valued at $25,000. Palisade Asset Management LLC purchased a new position in Ralliant during the third quarter valued at $26,000. V Square Quantitative Management LLC purchased a new position in Ralliant during the fourth quarter valued at $26,000. Allworth Financial LP lifted its position in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the period. Finally, BOKF NA purchased a new position in Ralliant during the third quarter valued at $29,000.

Ralliant Price Performance

Shares of NYSE:RAL opened at $66.00 on Friday. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $67.01. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The business has a fifty day moving average price of $53.04 and a 200-day moving average price of $49.83. The company has a market capitalization of $7.39 billion and a PE ratio of -6.03.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million during the quarter. The business’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts expect that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Wall Street Analysts Forecast Growth

RAL has been the subject of several recent research reports. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Citigroup raised their price objective on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Morgan Stanley raised their price objective on Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. TD Cowen raised their price objective on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Finally, Barclays raised their price objective on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $67.30.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.